Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What's Next For Bristol's Opdivo/Yervoy Combination

Executive Summary

Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.

Advertisement

Related Content

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Opdivo/Yervoy combo could be new standard in melanoma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065354

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel